Vocabria 30 mg Tablet
PDF Leaflet Revision Date: 4 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults who are virologically suppressed.
Dosage (summary)
30 mg once daily for oral lead-in; 600 mg IM initiation, then 400 mg IM monthly or 600 mg every 2 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; potential for fetal exposure.
Key Drug Interactions
- Rifampicin
- Rifapentine
- Phenytoin
- Carbamazepine
Contraindications
- Hypersensitivity to cabotegravir
- Concomitant use with rifampicin
Common side effects
- Injection site reactions
- Headache
- Nausea
- Rash
Counselling Points
- Adhere to injection schedule
- Monitor for hypersensitivity signs
- Avoid breastfeeding if possible
Serious warnings
- Hypersensitivity reactions
- Hepatotoxicity
- Risk of resistance after discontinuation
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
